Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
Javier Rodriguez-CarrioAgata BurskaPhilip Gerard ConaghanWillem A DikRobert BiesenMaija-Leena ElorantaGiulio CavalliMarianne VisserDimitrios T BoumpasGeorge BertsiasMarie Wahren-HerleniusJan RehwinkelMarie-Louise FrémondMary K CrowLars RonnblomEd VitalMarjan VersnelPublished in: RMD open (2023)
Evidence indicates potential clinical value of assays measuring IFN-I pathway activation in several RMDs, but assay harmonisation and clinical validation are urged. This review informs the EULAR points to consider for the measurement and reporting of IFN-I pathway assays.